Back to Search

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia


  • Protocol Number: 202001014
  • Principal Investigator: Ghobadi, Armin
  • Cancer Types: Gene & Cellular Immunotherapy, Lymphoma

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Protocol Interventions